FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences:
- TD Cowen 45th Annual Health Care Conference in Boston, MA
Fireside chat on Tuesday, March 4 at 1:50 p.m. ET, accessible here - Leerink Partners Global Healthcare Conference in Miami, FL
Fireside chat on Tuesday, March 11 at 3:30 p.m. ET, accessible here - Barclays 27th Annual Global Healthcare Conference in Miami, FL
Fireside chat on Thursday, March 13 at 9:00 a.m. ET, accessible here
Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
Contacts
Investor Contact
Kendra Sweeney
Kendra.sweeney@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
